Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis

There is growing concern that multiple sclerosis (MS) patients on certain therapies may be at higher risk for severe coronavirus disease 2019 (COVID-19). We conducted a systematic literature review to examine the available data on U.S. therapies approved to treat MS and the risk of SARS-CoV-2 infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Hada, Manila, Mosholder, Andrew D., Leishear, Kira, Perez-Vilar, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743352/
https://www.ncbi.nlm.nih.gov/pubmed/35006442
http://dx.doi.org/10.1007/s10072-021-05846-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743352/
https://www.ncbi.nlm.nih.gov/pubmed/35006442
http://dx.doi.org/10.1007/s10072-021-05846-3

Ejemplares similares